Corbus Pharmaceuticals (NASDAQ:CRBP) is set to announce its earnings results before the market opens on Thursday, November 8th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.
Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. The business had revenue of $0.85 million during the quarter, compared to analyst estimates of $1.90 million. On average, analysts expect Corbus Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NASDAQ:CRBP traded up $0.03 during midday trading on Tuesday, hitting $7.19. The company’s stock had a trading volume of 33,622 shares, compared to its average volume of 1,143,557. Corbus Pharmaceuticals has a fifty-two week low of $4.50 and a fifty-two week high of $9.95. The company has a market cap of $416.46 million, a PE ratio of -11.05 and a beta of 2.16.
Several equities analysts recently weighed in on CRBP shares. BidaskClub upgraded shares of Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 10th. Cantor Fitzgerald set a $32.00 price target on shares of Corbus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, July 25th. Finally, ValuEngine upgraded shares of Corbus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. Corbus Pharmaceuticals has an average rating of “Buy” and a consensus target price of $25.50.
TRADEMARK VIOLATION WARNING: This article was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/11/06/corbus-pharmaceuticals-crbp-scheduled-to-post-earnings-on-thursday.html.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes.
See Also: Earnings Per Share
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.